Background
Methods
Patient selection
Interventions
Follow-up
Endpoints
Statistics
Characteristics | Value | |
---|---|---|
Age (years) | Mean (SD) | 52.2 (10.6) |
Sex | Male | 1575 (85.3%) |
Female | 272 (14.7%) | |
HBV infection | No | 242 (13.1%) |
Yes | 1605 (86.9%) | |
Cirrhosis | No | 610 (33.0%) |
Yes (compensated/decompensated) | 1216 (65.9%)/21 (1.1%) | |
TBil (μmol/L) | Mean (SD) | 14.6 (6.2) |
Child-pugh | A | 1751 (94.8%) |
B | 96 (5.2%) | |
AFP | ≤400 ng/mL | 1255 (67.9%) |
> 400 ng/mL | 592 (32.1%) | |
γ-GT | ≤54 U/L | 947 (51.3%) |
> 54 U/L | 900 (48.7%) | |
Transfusion | No | 1739 (94.2%) |
Yes | 108 (5.8%) | |
Tumor number | Single | 1499 (81.2%) |
Multiple | 348 (18.8%) | |
Tumor diameter (cm) | Mean (SD) | 5.8 (3.8) |
ES grading | I&II | 172 (9.3%) |
III&IV | 1675 (90.7%) | |
Capsule | Present | 1487 (80.5%) |
Absent | 360 (19.5%) | |
Satellite | No | 1071 (58.0%) |
Yes | 776 (42.0%) | |
MVI | Present | 644 (34.9%) |
Absent | 1203 (65.1%) | |
BCLC | 0 | 107 (5.8%) |
A | 1446 (78.3%) | |
B | 294 (15.9%) | |
AJCC | Ia | 107 (5.8%) |
Ib | 938 (50.8%) | |
II | 623 (33.7%) | |
IIIa | 179 (9.7%) | |
CNLC | Ia | 846 (45.8%) |
Ib | 707 (38.3%) | |
IIa | 203 (11.0%) | |
IIb | 91 (4.9%) | |
PA-TACE | No | 1335 (72.3%) |
Yes | 512 (27.7%) |
Results
Clinicopathological characteristics of patients
Prognostics factors of HCC patients after radical resection
Characteristics | OS | DFS | ||||||
---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||
HR (95CI) | P-value | HR (95CI) | P-value | HR (95CI) | P-value | HR (95CI) | P-value | |
Age (years) | 1.00 (0.99–1.01) | 0.818 | 1.00 (0.99–1.01) | 0.852 | ||||
Sex (Male vs Female) | 0.95 (0.77–1.16) | 0.611 | 0.99 (0.84–1.18) | 0.950 | ||||
HBV infection (Yes vs No) | 1.01 (0.80–1.28) | 0.908 | 1.13 (0.93–1.38) | 0.208 | ||||
Cirrhosis (Yes vs No) | 0.95 (0.81–1.11) | 0.498 | 1.08 (0.95–1.24) | 0.237 | ||||
TBil (μmol/L) | 1.02 (1.01–1.03) | 0.003 | 1.01 (1.00–1.02) | 0.087 | 1.01 (1.00–1.02) | 0.010 | 1.01 (1.00–1.02) | 0.186 |
Child-pugh (B vs A) | 2.04 (1.54–2.70) | < 0.001 | 1.27 (0.93–1.72) | 0.131 | 1.72 (1.34–2.20) | < 0.001 | 1.13 (0.86–1.49) | 0.371 |
AFP (> 400 vs 400 ng/mL) | 1.66 (1.43–1.94) | < 0.001 | 1.43 (1.22–1.67) | < 0.001 | 1.35 (1.19–1.54) | < 0.001 | 1.22 (1.07–1.40) | 0.004 |
γ-GT (> 54 vs ≤54 U/L) | 1.76 (1.51–2.05) | < 0.001 | 1.38 (1.17–1.62) | < 0.001 | 1.69 (1.49–1.92) | < 0.001 | 1.42 (1.24–1.63) | < 0.001 |
Transfusion (Yes vs No) | 2.01 (1.54–2.61) | < 0.001 | 0.89 (0.66–1.22) | 0.479 | 1.97 (1.57–2.48) | < 0.001 | 1.12 (0.86–1.46) | 0.391 |
Tumor number (Multiple vs Single) | 1.83 (1.54–2.17) | < 0.001 | 1.50 (1.23–1.82) | < 0.001 | 1.82 (1.58–2.10) | < 0.001 | 1.53 (1.29–1.80) | < 0.001 |
Tumor diameter (cm) | 1.11 (1.09–1.13) | < 0.001 | 1.07 (1.05–1.09) | < 0.001 | 1.08 (1.06–1.09) | < 0.001 | 1.04 (1.02–1.06) | < 0.001 |
ES grading (III/IV vs I/II) | 1.80 (1.34–2.42) | < 0.001 | 1.28 (0.95–1.74) | 0.108 | 1.42 (1.13–1.78) | 0.003 | 1.08 (0.85–1.37) | 0.528 |
Capsule (Absent vs Present) | 1.42 (1.20–1.70) | < 0.001 | 1.35 (1.12–1.62) | 0.001 | 1.26 (1.09–1.47) | 0.002 | 1.16 (0.99–1.35) | 0.064 |
Satellite (Yes vs No) | 1.51 (1.30–1.75) | < 0.001 | 0.98 (0.81–1.18) | 0.812 | 1.46 (1.29–1.66) | < 0.001 | 1.05 (0.90–1.22) | 0.527 |
MVI (Absent vs Present) | 1.92 (1.65–2.23) | < 0.001 | 1.51 (1.27–1.79) | < 0.001 | 1.68 (1.48–1.90) | < 0.001 | 1.40 (1.22–1.62) | < 0.001 |
PA-TACE (Yes vs No) | 0.89 (0.75–1.05) | 0.165 | 0.93 (0.81–1.06) | 0.280 |
Relationship between patients’ γ-GT level and clinical characteristics
Characteristic | γ-GT ≤ 54 U/L (n = 947) | γ-GT > 54 U/L (n = 900) | P-value | |
---|---|---|---|---|
Age (years) | Mean ± SD | 52.3 (10.5) | 52.1 (10.6) | 0.778 |
Sex | Female | 182 (19.2%) | 90 (10.0%) | < 0.001 |
Male | 765 (80.8%) | 810 (90.0%) | ||
HBV infection | No | 139 (14.7%) | 103 (11.4%) | 0.047 |
Yes | 808 (85.3%) | 797 (88.6%) | ||
Cirrhosis | No | 315 (33.3%) | 295 (32.8%) | 0.863 |
Yes | 632 (66.7%) | 605 (67.2%) | ||
TBil (μmol/L) | Mean ± SD | 14.2 (5.54) | 15.1 (6.78) | 0.003 |
Child-pugh | A | 925 (97.7%) | 826 (91.8%) | < 0.001 |
B | 22 (2.3%) | 74 (8.2%) | ||
AFP (ng/mL) | ≤400 | 662 (69.9%) | 593 (65.9%) | 0.072 |
> 400 | 285 (30.1%) | 307 (34.1%) | ||
Transfusion | No | 926 (97.8%) | 813 (90.3%) | < 0.001 |
Yes | 21 (2.2%) | 87 (9.7%) | ||
Tumor number | Single | 799 (84.4%) | 700 (77.8%) | < 0.001 |
Multiple | 148 (15.6%) | 200 (22.2%) | ||
Tumor diameter (cm) | Mean ± SD | 4.60 (2.64) | 7.17 (4.33) | < 0.001 |
ES grading | I/II | 99 (10.5%) | 73 (8.1%) | 0.097 |
III/IV | 848 (89.5%) | 827 (91.9%) | ||
Capsule | Present | 770 (81.3%) | 717 (79.7%) | 0.405 |
Absent | 177 (18.7%) | 183 (20.3%) | ||
Satellite | No | 572 (60.4%) | 499 (55.4%) | 0.035 |
Yes | 375 (39.6%) | 401 (44.6%) | ||
MVI | Present | 311 (32.8%) | 333 (37.0%) | 0.068 |
Absent | 636 (67.2%) | 567 (63.0%) | ||
BCLC | 0 | 79 (8.3%) | 28 (3.1%) | < 0.001 |
A | 755 (79.8%) | 691 (76.8%) | ||
B | 113 (11.9%) | 181 (20.1%) | ||
AJCC | Ia | 79 (8.3%) | 28 (3.1%) | < 0.001 |
Ib | 495 (52.3%) | 443 (49.2%) | ||
II | 322 (34.0%) | 301 (33.4%) | ||
IIIa | 51 (5.4%) | 128 (14.2%) | ||
CNLC | Ia | 549 (58.0%) | 297 (33.0%) | < 0.001 |
Ib | 285 (30.1%) | 422 (46.9%) | ||
IIa | 90 (9.5%) | 113 (12.6%) | ||
IIb | 23 (2.4%) | 68 (7.6%) | ||
PA-TACE | No | 707 (74.7%) | 628 (69.8%) | 0.022 |
Yes | 240 (25.3%) | 272 (30.2%) |
The relationship between γ-GT level and the prognosis of patients
Characteristics | OS | DFS | ||||||
---|---|---|---|---|---|---|---|---|
Before PSM | After PSM | Before PSM | After PSM | |||||
HR (95CI) | P-value | HR (95CI) | P-value | HR (95CI) | P-value | HR (95CI) | P-value | |
γ-GT ≤ 54 U/L | ||||||||
Tumor number (Multiple vs Single) | 2.11 (1.55–2.87) | < 0.001 | 1.97 (1.33–2.93) | 0.001 | 2.07 (1.61–2.65) | < 0.001 | 2.18 (1.59–2.98) | < 0.001 |
Tumor diameter (cm) | 1.11 (1.07–1.15) | < 0.001 | 1.11 (1.05–1.17) | < 0.001 | 1.08 (1.04–1.12) | < 0.001 | 1.08 (1.03–1.13) | 0.003 |
Capsule (Absent vs Present) | 1.36 (1.02–1.81) | 0.039 | 1.41 (0.95–2.09) | 0.085 | – | – | – | – |
MVI (Absent vs Present) | 1.58 (1.22–2.06) | 0.001 | 1.57 (1.10–2.26) | 0.014 | 1.44 (1.16–1.79) | 0.001 | 1.45 (1.08–1.95) | 0.014 |
PA-TACE (Yes vs No) | 0.85 (0.65–1.11) | 0.222 | 0.89 (0.64–1.23) | 0.471 | 0.86 (0.69–1.08) | 0.190 | 0.91 (0.71–1.18) | 0.483 |
γ-GT > 54 U/L | ||||||||
TBil (μmol/L) | 1.01 (1.00–1.03) | 0.036 | 1.02 (1.01–1.04) | 0.009 | 1.01 (1.00–1.03) | 0.028 | 1.03 (1.01–1.05) | < 0.001 |
AFP (> 400 vs 400 ng/mL) | 1.71 (1.39–2.10) | < 0.001 | 1.71 (1.32–2.22) | < 0.001 | 1.43 (1.20–1.71) | < 0.001 | 1.47 (1.18–1.84) | 0.001 |
Tumor number (Multiple vs Single) | – | – | – | – | 1.25 (1.01–1.56) | 0.042 | 1.08 (0.82–1.42) | 0.589 |
Tumor diameter (cm) | 1.06 (1.04–1.09) | < 0.001 | 1.07 (1.04–1.10) | < 0.001 | 1.03 (1.01–1.05) | 0.008 | 1.04 (1.01–1.06) | 0.005 |
Capsule (Absent vs Present) | 1.33 (1.05–1.68) | 0.019 | 1.43 (1.05–1.95) | 0.024 | – | – | – | – |
MVI (Absent vs Present) | 1.43 (1.14–1.79) | 0.002 | 1.21 (0.89–1.64) | 0.219 | 1.37 (1.13–1.65) | 0.001 | 1.19 (0.92–1.54) | 0.174 |
PA-TACE (Yes vs No) | 0.69 (0.55–0.86) | 0.001 | 0.66 (0.52–0.85) | 0.001 | 0.76 (0.63–0.91) | 0.003 | 0.74 (0.60–0.92) | 0.006 |